Natural products matter, for they are essential contributors to societal well-being and global health. Flavors, fragrances, essential oils, traditional medicines and phytopharmaceuticals, and prescription and over-the-counter products all utilize constituent materials from natural sources. However, these vast natural resources of Earth are disappearing, and climate change and market expansion by a dramatically increasing and ageing population will continue to strain plant sourcing in the decades ahead. It was with these and other considerations that the term "ecopharmacognosy" was developed as both a philosophy and a practice, and from which the necessity for a "medicines security" strategy evolved.
Natural Product Communications Vol. 12 (8) 2017
Cordell we have named Earth. It is the place which currently 7.54 billion of the human species Homo sapiens, and may be 2 million other species, call "home". In the Anthropocene period, this "cash", Earth's resources, is being drawn down staggeringly fast, with no respite in sight. Even our efforts to deposit "cash" back into the bank, such as reforestation and the creation of nature preserves and national parks, fall dismally short of what has been, and is being, irreplaceably lost, daily. The Anthropocene epoch is described as a time when the contemporary activities of humankind impact (usually negatively) the quality of human life for future generations [18, 19] . It was the actions of humans which led, in 1662, to the extinction of the "dodo", Raphus circullatus Brisson (Columbidae) on the Island of Mauritius; an event that was perhaps the start of the documented Anthropocene epoch. Numerous undocumented extinctions of species, such as the many land birds of the Pacific Islands, can also be attributed to human encroachment, and since those early human migratory movements thousands of years ago, we have become the most destructive species on the planet, all the while presupposing that we are the most sentient and intelligent [20] .
In mid-2015, the Rockefeller-Lancet Commission on Planetary Health issued a report [21] which concluded that "We have mortgaged the health of future generations to realize economic and development gains in the present". The Commission suggested that societies must "address the drivers of environmental change by promoting sustainable and equitable patterns of consumption, reducing population growth, and harnessing the power of technology for change." These conclusions were supported by extensive documentation and analyses regarding various aspects of the anthropogenic impact on Earth from evolving lifestyles and human demographics.
More specifically with respect to plants and the planet Earth, the Royal Botanic Gardens at Kew in England recently presented their findings on the "State of the World's Plants" [22] . It was concluded that there are now approximately 392,730 vascular plants, with, on average, about 2,000 new plant species being identified each year. However, approximately one-fifth (21%) of all flowering plants are presently under threat for a variety of reasons, and only 225 plant genomes have been completed. The Kew report estimates that 28,187 (7.18%) of plants have been, or are being, used for their medicinal purposes in the world, while more than 10% of Earth's vegetation is in areas of the world with a high sensitivity to climate change.
The prime mitigators of planetary health are loss of habitat, of biodiversity, and of traditional knowledge, coupled with climate change, and time, each derived from the living styles of a burgeoning population [16] . It is abundantly clear that there are already too many people presently living on Earth to be supported at even a moderate level of resource utilization. Governments, many global and national enterprises, the public, and the leaders of all of the dominant religions have yet to acknowledge and grasp this fundamental fact, and act and advise appropriately. For those responsible, looking 15 years ahead, let alone 30 or 40 years, and envisaging and then planning for how that world will accrue the necessary resources seems not to be a responsible option. Naïvely, based on the expectations of an ever-expanding global corporate enterprise, it is apparently felt that problems can be solved as they arise, or that there is, or will be, no problem. Some would indicate that the scientists are alarmist and self-serving. That view is not a sustainable model for the projected lifestyle of future generations. In the past, this author has compared the contemporary situation to Alice's Adventures in Wonderland where the grinning Cheshire Cat makes it clear to Alice that "We're all mad here!" [13, 23] . Is restoration of some modicum of sanity possible by developing an alternative perception of natural products for 2030, through outlining the present state of affairs and posing some long-term challenges? What are the implications of these changes for the accessibility of the medicinal agents needed in the future by the global population for preventive, palliative, and curative purposes?
The World in 2030
The global population in 2030 is estimated to be in the range of 8.3-8.5 billion, a net increase of 11.6-14.2%, or roughly a 1% increase annually [16] . That population, according to a United Nations report in 2012, is estimated to need 50% more food, 45% more energy, and 30% more water than the current global population, as living standards evolve in the developing world and as urban migration continues. Critically, from a resource perspective, the middle-class population is expected to expand by 3 billion by about 2030 [24] .
At that time, the world will be even more fully interconnected with respect to access to goods, services, the monitoring of our daily lives, self-actuated, industrially, and governmentally.
The acquisition of information from global resources will be even faster, more penetrating, and more integrated in more countries. Our online, life demographic profiles will feed us unrelenting data streams and interconnected "advice". Higher levels of robotics and automation with respect to consumerism, housing, cars, trains, and aerial transportation will be evident in much of the developed world. And the status of medicines? According to the World Bank, there will be some form of universal health care in place in most countries, which will inevitably lead to higher health demands as population numbers increase, and particularly as the population ages through increased life expectancy to 85 for men, and perhaps 90 for women, in much of the world (vide infra).
The most important, yet essentially unmeasurable, factor which overshadows all future thinking about health care is climate change. How much warmer will it get? Where will that occur? Which areas will change in terms of rainfall and sea level, and by how much, and over what period of time? From the point of view of this discussion, what will be the impacts on disease distribution, particularly vector-borne and contagious diseases? How will the growth and secondary metabolite production of microbes, marine animals, medicinal plants, and their symbiont organisms, change under conditions of climate modulation?
Climate Change
The climate of Earth is changing……fast. Shrinking glaciers and the earlier breaking apart of ice floes on rivers and lakes, shifting ranges for plants and animals, an accelerated rise in the sea levels, an increase in the global average temperature, and the changing intensity of weather patterns are cumulative evidence for the significant climate change presently occurring on the planet [25, 26] . These trends are predicted to continue, and average air temperatures are postulated to rise 1-4 degrees Celsius over the coming decades in a manner that is neither even across the planet nor necessarily deleterious. There will be some areas of the world which will benefit and others where great harm will be done. Sea levels may rise from 0.5 to 1.2 meters within the next 70 years. The costs of these changes over time will be several trillion USD, and the mollification of these effects is now beyond our capacity. In the US, one area of particular susceptibility is coastal Florida and the Atlantic Ocean coast, where a combination of rising sea levels and 2030 Challenges for natural products Natural Product Communications Vol. 12 (8) 2017 1373 decreased water availability will have major environmental and agricultural impacts [25, 27] . The Intergovernmental Panel on Climate Change has summarized those areas around the world which are projected to be the most susceptible to various aspects of climate change [26] . Examination of these highly vulnerable areas indicates that they are typically also those areas of the world where there is limited access to Western medicine. Furthermore, those coastal areas which are growing medicinal plants for local or national needs may be dramatically affected, especially by the increased salinity of the environment.
Some studies are available which have examined the growth and metabolite production of medicinal and essential oil plants under conditions of increased salinity and drought [28] [29] [30] [31] .
For Catharanthus roseus (L.) G.Don (Apocynaceae), increased salinity decreased growth characteristics, and increased alkaloid content [28] , while for Matricaria chamomilla L. (Asteraceae), no effects were observed for a salinity up to 84 mmol NaCl, however, both flower weight and essential oil content were reduced in drought conditions [29] .
Geraniol and citral levels were increased significantly in two species of lemongrass, Cymbopogon nardus (L.) Rendle var. confertiflorus (Steud.) Stapf ex Bor and C. pendulus (Nees ex Steud.) Will.Watson (Poaceae) when they were drought-stressed for 45 and 90 days [30] . Saikosaponin production in the traditional Chinese medicine Bupleurum chinense DC. (Apiaceae) was also increased under reduced water-stress conditions [31] . Additional studies are urgently needed on important medicinal and essential oil-yielding plants under drought, water-excess, and conditions of varying salinity to examine more closely the production levels of biologically-relevant and economically important metabolites, as this may significantly affect the recommended dosing levels or isolation yields. The present evidence indicates that specific changes in metabolite levels under modified conditions are not predictable, and will undoubtedly depend on modulations incurred by the regulatory genes of biosynthetic pathways and their individual responses. Clearly, there will also be a significant economic impact.
The overall effects of climate change on agriculture yields have been modeled in several studies [32] [33] [34] [35] [36] , although none of them dealt with medicinal plants. The importance of the integration of climate variability into modeling, and the risks to maintaining growing sites for specific medicinal and essential oil plant crops, need to be studied, as well as more multidisciplinary studies and policy approaches using a wider range of scales than were previously considered [32] . This is of critical importance for subsistence and smallholder farmers [33] , since these are the field environments which presently produce many of the "cultivated" medicinal plants in the local wholesale and retail markets, and where adaptive capacity will be critical in the future. "Food security" was mentioned earlier as a major global concern, and has been the subject of climate change studies. Of the four prime elements of food security, availability, stability, utilization, and access, it was mentioned that only availability is typically a factor in modeling studies. One report [34] examined some of the other factors, including the changing stability of the produced crops (food safety), whereby a cycle of infectious disease, including salmonellosis, diarrheal diseases, and cholera, set in. This is a global public health issue, since it is estimated that many millions of additional people (up to 170 million) will likely be undernourished by 2080. The amplification of the distribution of harmful algae, which produce saxitoxin and the complex polyether polyketides, such as okadaic acid and yessotoxin in fish farms and in coastal marine environments, is an important food safety factor [37, 38] . A further study, highly relevant, and not yet applied to medicinal plants, examined the cost changes in the market place for certain food crops under various agricultural scenarios, and projected a 10-60% price increase by 2030, based on climate change alone [35] . One critical aspect of ecopharmacognosy is that of accessibility to traditional medicines, which embraces both sustainability (is the plant available?) and affordability (can the local populace still buy the medicinal material?) [6, 8, 12, 39] .
Broadening the scope of assessing vulnerability to increased health risks as a result of climate change was discussed in a review examining various health outcomes based on studies of climate variation and the incidence and spread of various infectious diseases, including salmonella and cholera [40] . More significant may be changes in the prevalence, geographic range, and transmission of several vector-borne diseases, such as malaria, dengue fever, chikungunya, yellow fever, viral encephalitis, schistosomiasis, leishmaniasis, onchocerciasis, and Lyme disease, as discussed in a major series of reviews by the World Health Organization of the impacts of climate change on human health [41] . Specific areas of the world where there are projected increases in mortality related to climate change have also been identified [42] . Particularly vulnerable regions included some temperate latitudes, the regions within the Pacific and Indian oceans which are affected by the El Niño/Southern Oscillation rainfall variability, sub-Saharan Africa, and the sprawling cities of the developing world. On the other hand, detailed modeling of the distribution of malaria indicates that, although mortality has dropped significantly in recent years (to 655,000 in 2010) due to vector control methods, the highlands in Eastern Africa, and parts of South America and southeastern Asia are likely to witness increases in disease prevalence by 2030 and beyond [43] . In many of these areas, medicinal plants remain the primary form of health care, and thus provisions for their sustainable accessibility are essential. Clearly, many studies need to be conducted at the national and local levels to examine how these projections of potential deleterious vector changes might impact at the local level, where the outcome, is on lives and livelihoods, not numbers or trends.
The Centers for Disease Control (CDC) in Atlanta, GA, USA, has provided a stunning graphic on the impacts of climate change on global health [44] . It illuminates four areas of change: rising temperatures, more extreme weather, rising sea levels, and increasing levels of carbon dioxide. From a disease perspective, among the effects these changes are projected to cause, in addition to vector ecology, are the enhanced incidence of diseases related to changing water supply and quality, and an increasing incidence of allergens, which increases the risks of respiratory illness and asthma. It is pertinent to ask whether there are adequate drugs available, or in the development pipeline, to meet these projected needs and those of the vector-borne diseases mentioned above? Given the time frame of 12-20 years to develop an FDA-approved drug, new initiatives are needed in the immediate future, as part of a global strategic plan for assured, effective drug availability for 2030 and beyond from the World Health Organization. In September, 2016 a new initiative based in the UK on the development of drugs to overcome multiple drug resistance was announced by the United Nations.
"Medicines security" can be parsed in the same way that "food security" is defined by the Food and Agriculture Organization (FAO) [45] . In parallel, it may be defined as a "situation that exists when all people, at all times, have physical, social, and economic access to sufficient, safe, and effective medicines that meet their prophylactic and treatment needs for an active and healthy life".
Cordell
There are four elements to this definition for medicines: availability, stability, access, and utilization. The first aspect relates to the availability of medicines, whether derived from synthetic and/or natural sources. It includes the continuing availability of approved and needed medicines, even when their use is limited in scope (as for an orphan disease). In terms of natural medicines, this should reflect the transition of important plant and other biologically active natural sources from wild crafting into sustainable, cultivated crops.
The second aspect, stability, refers to situations where a change in circumstance may reduce the ability to afford a previous medication. This may happen for seasonal workers in any field (construction, agriculture, etc.), or when manufacturing plants are closed or moved, and there is no coverage by national or private insurance. In this context, access is applied to situations where, due to high cost, synthetic medicines are not an economic option, and, due to climate variability, or as the medicinal plants are unsustainably cropped from the forests, or other factors (e.g. commercial development of forest areas), they are not a reliably harvested commodity, and supplies from alternative sources are too costly. Utilization covers all of the aspects of quality, safety, efficacy, and consistency (QSEC) [8] [9] [10] [11] [12] [13] [14] of pharmaceuticals, traditional medicines, and dietary supplements in order to either prevent or treat a disease state. Many diverse financial factors abound within these four elements, and are not within the purview of the present discussion.
The Sixty Challenges for Natural Products
With this summarizing background of the present, and some brief projections of the future world in 2030, it is time to challenge some aspects of contemporary natural product thinking. It is important to consider what advances, changes, and outcomes might be possible within the time frame of 13 years in terms of global natural products, particularly with respect to their role in health care. The first challenge, which is not one of the sixty challenges, concerns the very fundamental model of natural products in health care. Currently, particularly with respect to traditional medicines, dietary supplements, and phytotherapeuticals, the existing model has the industry as the dominant focus, with a small relevance for regulatory authority, for science, and the patient. From the perspective of anticipated patient outcomes this is no longer an acceptable, ethical structure for optimal health care. The proposed new model for traditional medicines and dietary supplements [14] places the patient at the center of the functional construct, optimally served by regulation, by science, and by the manufacturer. How can this reconstruct move closer to a reality?
Listed below, and not in any prioritized order, are the sixty "challenges"; considerations for natural product development in the future which require contemplation for future investment to promote innovation and address the numerous and vast, global health care "gaps". These challenges, posed as "Can" questions, also address advancing the use of high-quality, evidence-based traditional medicines in health care, while viewing medicines as an essential requirement for human and animal life, and thus to be sustainably developed, irrespective of their origin, synthetic or natural. "Can" implies willingness, dedication, and financial support, and is typically not related to feasibility or intellectual ability. This list should not be regarded as comprehensive, since several areas of the role of natural products in society and health care (nutraceuticals, cosmeceuticals, for example) are not specifically presented. The sixty challenges are categorized as: General, Sustainability, Patients, Traditional Medicine, Technology, Secondary Metabolism, Plant Analysis, Synthesis, and Publications. General i) Can constituent international and regional scientific groups and organizations collaborate and gain a "voice" to promote the importance of natural products and their roles in society, particularly as medicinal agents or adjuvants for global health care? ii) Can intellectual property rights conflicts between the CBD/Nagoya Protocol and the TRIPS agreements be resolved to enhance investment in natural product development? iii) Can groups (international orgs, NGOs, companies, academia, and regulators) come together to work for improved, integrated health care systems, based on natural products? iv) Can multicenter, international collaborative research programs be developed aimed at enhancing traditional medicine and phytotherapeutical product quality, safety, efficacy, and consistency? v) Can the internet sale of TMs and natural products be regulated to enhance patient protection from fraud? Sustainability i) Can all medicines, natural and synthetic, be regarded as a sustainable commodity, and the needs for 2030 et seq. be met through sustainable sourcing? ii) Can the impact of climate change on the accessibility to TMs be assessed and ameliorated to foster the sustainable sourcing of plants for health care? iii) Can traditional medicine research be placed on a sustainable basis by manufacturing companies? iv) Can medicinal plant genome resource centers be established to preserve critical medicinal plants for the future? v) Can waste products from food, medicinal plant, and essential oil processing be developed for the isolation of compounds for: a) drug synthesis, b) the potentiation of synergistic drug activity, or c) overcoming drug resistance? vi) Can natural product research be made more energy and fiscally efficient, less wasteful of resources, and more effective for society? (The "green chemistry" aspect of ecopharmacognosy.) vii) Can the declaration of "activity" for a metabolite in a biological assay be related to the relevance of what a sustainable human daily dose would be in the event of medicinal agent development? Patients i) Can traditional medicines be developed to become consistent, safe, and effective, and remain accessible to a global population? ii) Can the translation of meaningful research results on traditional medicines and phytotherapeuticals to products and practice be made more effective for patient benefit? iii) Can evidence-based, ineffective TMs be eliminated from practice? iv) Can "What's in a Name?" for a TM product become a patient reality? In other words, can patients be appropriately protected from adulterated and contaminated TMs? v) Can an effective medicine balance be struck between "Western-based" medicinal agents and those derived from TCMs, Ayurveda, etc. to optimize affordable and integrated care for a more diverse population? vi) Can effective, global, adverse drug reaction data systems for traditional medicines and phytotherapeuticals with other medicinal agents be developed to enhance the safety and efficacy of polypharmacy? Traditional medicine i) Can the 300 most important traditional medicinal plants that must be sustainably developed be identified and conserved? ii) Can the global harmonization of the diverse regulations applied to traditional medicines become a reality?
Natural Product Communications Vol. 12 (8) 2017 1375 iii) Can a new category of standardized, accessible effective natural product preparations be developed for clinical use in developing countries? iv) Can evidence-based TM products be regulated other than as "drugs", and limited claims be allowed in developed countries? v) Can traditional medicines, using an evidence-based approach, fill some of the chasms in health care with respect to drug therapy for the prevalent diseases of the majority? vi) Can network pharmacology reduce the biological requirements (and therefore the time and cost) for the approval of medicinal agents in both the developing and developed worlds? vii) Can a global database of the summed knowledge (cultural and scientific) of traditional medicine and medicines be created and developed for open access? viii) Can the optimum times for accessing, and the methods for processing, a medicinal plant be determined? ix) Can the origin(s) of the biological activity of medicinal plants be traced to the plant metabolites or to plant-associated microbial metabolites? x) Can metabolomics answer critical analytical questions to optimize TM cultivation and to understand the outcomes of natural products on animal and human metabolism? xi) Can the importance of the secondary metabolites in foods and spices, as modulators of pharmaceutical care, be established? xii) Can the illicit trade in threatened and endangered medicinal products (rhino horn, bear gall bladder, bear paw, etc.) be stopped? Technology i) Can the important emerging spectroscopic, chromatographic, remote sensing, and deep learning technologies be continuously integrated into the natural product sciences? ii) Can databases for the on-line searching of raw proton and carbon-13 NMR and mass spectral data of natural products be developed? iii) Can the microfluidics, biosensors, and in silico technologies needed to conduct effective "pharmacognosy in a suitcase" be integrated and mobilized? iv) Can new TMs and individual drugs be developed, based on in silico network pharmacology databases of purified natural products, to address important global health care needs? v) Can the expanded use of in silico screening techniques enhance the discovery of lead molecules, including those for orphan diseases? vi) Can synergistic and antagonistic effects within complex TMs be predicted and the mixture rationalized, thereby eliminating unnecessary plants and enhancing sustainability and improving patient outcomes? vii) Can the "innovation deficit" of natural products in the US be eliminated or dramatically reduced? viii) Can chromatographic methods be developed which rapidly separate a complex natural product matrix by molecular size and biological function (microSPE-microLC systems)? ix) Can a plant be identified, and its properties, chemistry and uses be made available using a digital image, through the integration of diverse natural product data sets? x) Can a hand-held device be developed for the stand-off assessment of medicinal plants to optimize cultivation? Secondary metabolism i) Can secondary metabolite production be monitored in "real time"? ii) Can the complete secondary metabolic profile of a plant be determined? iii) Can the metabolic pathways of a plant be assembled and regulated in vitro (yeast, bacteria) to produce only those metabolites which are of medicinal or biological importance? iv) Can new classes of antibiotics, which will not develop resistance, be discovered through microbial genome mining? v) Can dormant secondary metabolic pathways for new natural product scaffolds be discovered in plants? Plant analysis i) Can plant extraction, separation, purification, and identification be conducted using the most sustainable technologies? ii) Can a consolidated database of the DNA barcodes of all traditional medicines be achieved? iii) Can the UHPLC-MS n analysis of a plant extract be made extremely fast (< 5 min), and concomitant with the preliminary database identification of the metabolites? iv) Can automated compound isolation and characterization from a crude plant or organism matrix be achieved? v) Can molecular networking be used to discover new botanical relationships, and for the drug discovery of biologically active metabolites? vi) Can synthetic active site receptors be developed to separate active principles and quantitate them directly for standardization? Synthesis i) Can vegetables, or other sustainable and recyclable natural, diverse reagents become an integral aspect of the production of both drugs and chemicals? ii) Can the complete synthesis of a complex drug molecule be achieved using only recyclable and/or renewable reagents? iii) Can plants be engineered to produce renewable organic chemicals for synthesis? Publication of results i) Can the reliance on for-profit, scientific journals for the distribution of scientific information be significantly diminished? ii) Can all research publications be retained as the property of the creators, the scientists? iii) Can all research that is submitted for publication be published, and then filtered through post-publication review, which may lead to recalibration (editing, withdrawal, and/or resubmission) over an extended period? iv) Can the publication process of submission, review, and editing be made completely transparent and accountable, with attributed reviews (comments) readily available? v) Can data assembly, literature background, and qualified commentary of the context of the results for research publications be prepared mostly through manuscript assembly algorithms? vi) Can research publications be instantly and completely translatable into the major global languages? (Thereby eliminating the need to write in English!!)
Genomics and the Future Development of Natural Products
Underpinning many aspects of the development of natural products for the long-term future is a deep understanding of how metabolites are synthesized naturally, where, and how long that process takes, and whether biologically and commercially important molecules can be assembled expeditiously and completely in heterologous sites. Additionally, the sequencing of bacterial genome systems [46] [47] [48] [49] has revealed that even "simple" organisms are packed with untapped biosynthetic capacity, where a few isolates may have been characterized from one pathway, and genomic evidence supports the existence of may be 25 or more additional secondary metabolite biosynthetic gene clusters, as demonstrated for Streptomyces avermitilis and S. griseus [50] [51] [52] . If these numbers obtained through bioinformatics-designated cluster scanning for unusual
Cordell genes are translatable to other bacterial genomes, then their relationship to other established gene clusters in terrestrial and marine native and symbiont microbial systems becomes an important measure of the high potential for the discovery of new natural product scaffolds and their subsequent tailoring. Such in silico strategies, keenly in line with the philosophies of ecopharmacognosy, will allow those new biosynthetic gene cluster constructs to be targeted prior to culturing and isolation/dereplication. Turning to plants, where significantly less is known about secondary metabolic genes, in part because they are fragmented, it is probably the case that several additional classes of plant-derived natural product remain to be uncovered for biological assessment, or that new sources of known desirable natural products may be identified. The ability to accumulate and assemble the requisite, plant-derived genes for the complete secondary metabolite production of valuable opiate alkaloids in a heterologous organism was recently demonstrated in yeast [53] and in E. coli [54] . These events represent a huge practical step forward toward the realization of assuring a renewable, sustainable supply source for a medicinal agent, irrespective of its source. This is a foundational pillar of ecopharmacognosy and for the development of natural product medicines security.
In the future, four major areas of genetics will dramatically impact these aspects of metabolite discovery and production [49] . Genomics and bioinformatics will be predicting the nature of the products from previously unexplored biosynthetic gene clusters, microbial ecology will examine how the genes for metabolite formation are distributed in the terrestrial and marine organisms on Earth, which will indubitably provide a nexus for intellectual property rights issues. Synthetic biology will expand into exploring the substrate specificity of encoded genes to specifically engineer new or known metabolic pathways and express them in insects, yeast, and E. coli. Meanwhile, systems biology is projected to unravel the regulatory issues related to natural product formation and, through metabolomic networking, explore the complexity and interrelationships of natural product biosynthesis in an organism. The enhanced production of medicinal natural products and essential oils will undoubtedly be an important factor as Earth's population continues to increase, and as enhanced life expectancy becomes a major contributing factor to these intensified natural product requirements.
Life expectancy and Ecopharmacognosy
In the United States in 1900, life expectancy at birth was about 47.5 years, by 2000 it had reached 77 years, and is projected to reach 84.3 years by 2050 for women, and 79.7 years for men [55] . One eleventh of baby-boomers (those born between 1946 and 1964) will live to their late 90s, and one in 26 will reach 100 by 2060. That represents about 3 million US centenarians, compared with 3,700 in 1940, a staggering demographic change. Another assessment, based on six developed countries (excluding the US), indicates a steady linear increase in life expectancy from ca. 47 years to 85 years over the period 1840-2000 for women (about 3 months every year) [56] . In the US, the major mitigating factor against enhanced life expectancy appears to be the rapid rise in obesity, and the cardiac, diabetic, and other complications that condition brings [57] . What does such a major shift in longevity mean in terms of resource requirements, both generally, and, more specifically, for the sustainable provision of synthetic and natural medicines? These implications relate directly to ecopharmacognosy in terms of an enhanced population in those areas of the world where traditional medicine use is the most prevalent and where access to Western medicines is especially limited.
The population of Earth will become significantly older, even in the next 15 years as birth rates continue to decline, which will increase sustainable supply demands on medicinal plants, as use is greater in the middle-aged and elderly populations [58] . Furthermore, the blending of medication practices, polypharmacy, is also more prevalent in older persons [59, 60] , which increases the use of both prescription and phytotherapeutical products. Analyzing the need for sustainable medicinal plants in an emerging, ageing population model would therefore seem to be an important global research area for governments and corporations to collaboratively develop accessible (sustainable and affordable) products to meet future patient requirements as part of a larger program of embracing medicines security as a policy issue.
Handheld Ecopharmacognosy and Deep Learning
By 2030, artificial intelligence (AI) will become a fundamental aspect of, and the basis for, effective natural product research, especially for ecopharmacognosy. One of the long-term goals of spectral consolidation and data integration has been automated structure elucidation. This level of data processing and analysis is already being experienced in aspects of automated NMR and mass spectral analysis [61] ; although, as discussed elsewhere [14] , human supervision of the output in terms of rational natural product identification is still necessary.
This impact, with further consolidation of botanical, chemical, biological (network pharmacology), and quality control databases, will expand dramatically, and fundamentally, modify the role of identified natural products in health care.
The internet system Baidu can now perform facial recognition with 99.77% accuracy, with four other recognition systems close behind [62] . Imagine in a few years speaking (as a smart phone user now contacts voice-activated data services) to "GANP", the "Global Archive of Natural Products". You take a photo of a plant in the field. "GANP, can you give me a summary of the principal metabolites and the most potent biological activities of the leaves of this plant?" Five-milliseconds later the screen responds with reams of citations and data, and a charming voice says "Thank you for your questions. This plant is Catharanthus roseus, the rosy periwinkle. It contains over 120 monoterpene indole alkaloids. Some of the alkaloids and their derivatives, including vincristine and vinblastine, are used in the treatment of cancers. Do you have other questions about this plant? I have a lot more information available." A simple example, and probably doable within five years. A more complex question may take a little longer (~20 milliseconds) to answer before the systems rejoin. For example, after taking a hand-held Raman laser scan of a plant, then asking: "GANP, is this the best time to harvest this plant?" Or "GANP, what are the twenty best sustainable plants to study for treating diabetes, and where are they found?" It will be the beginning of handheld ecopharmacognosy.
The current availability of such data retrieval services, Google Scholar is an important example, has occurred due the development of interwoven ecosystem environments for deep data analysis, sometimes referred to as deep learning, whose effectiveness is based on 30 or more layers of "weighted" neural networks, and whose speed has been dramatically enhanced through the introduction of video game graphical processing units (GPUs). These units provide highly targeted outcomes originating in a full or partial learning environment, where, over time, the accuracy of a response improves [62] .
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There is at present no means through which the natural product community can share data effectively and in a timely manner; the only resource is the literature, there is no series of nodes for extensive database networking. Consequently, the data that are generated from various hyphenated analytical and spectroscopic techniques that are used for metabolite profiling [63] and multidimensional mass spectrometry imaging [64] are typically built up at the local site of interest, and are not generally available. A global effort to accumulate large datasets on the mass spectrometry of natural products was recently described [65] . Other cumulative, integrated spectral and chromatographic databases are needed. Hopefully, this will pave the way for future developments in massive data acquisition through community involvement and input, and will provide global open access to those datasets as an integrated network resource.
Unlike many newer fields of science, botany, natural products chemistry and biology, traditional medicine, and the pharmaceutical and pharmacopoeial sciences are each incredibly data-rich. These data sets, beginning with ethnopharmacological reports, are based on hundreds of thousands of published articles, chapters, books, etc., some of which have accumulated knowledge from well over two thousand years of experience, and which necessitates experimental investigation.
Additionally, there is now the burgeoning data originating from the DNA barcoding of plants, the sustainability of the plants, the spectral, chromatographic, and crystallographic data of isolated natural products, the metabolomics of plant extracts and plant processing, the conformational analysis of compounds, the structures and active sites of proteins and their substrates, the genomic data on plant and microbial organisms, and the biological responses and network pharmacology of individual compounds and extracts. These data need to be interconnected and integrated.
As more of these data-suffused fields are intertwined electronically, the accumulated data will become overwhelming from a human perspective, requiring partially and fully unsupervised learning to be applied. Structure elucidation will be essentially automated for all the known, natural constituents in an extract. High probability suggestions will be automatically developed for unknown isolates. This technology will also be able to discern specific pattern recognition algorithms for aligning morphological, DNA-based taxonomy and chemotaxonomy, as they evolve through continuous analysis and refinement. The application of such processes, interlaced with information from network pharmacology of extracts and isolates, may provide specific, new, potential lead molecules for a recognized disease state (for a contemporary example, vide infra). Ideally, this would immediately indicate a preferred sustainable resource, and its location and growth characteristics.
Over time, structure activity relationships will evolve through the broader applications of network pharmacology, and these continuously expanding vast datasets will enhance the sophistication and directivity of the outcome for new drugs. This would approximate to an artificial general intelligence (AGI) for all natural products and for their societal impact. Language diversity within the data sets would not be a barrier to data analysis, as translation is already almost instantaneous. How far away is that discovery system as a reality, 15 years? Is it a realistic target for 2030? Undoubtedly. After all, with real-time translation at that time, we will speak in our own language and be heard immediately in Spanish, Polish, Japanese, Chinese, etc.
Two examples will illustrate some contemporary aspects of AI and drug discovery. From a biological discovery perspective, one of the facets of ecopharmacognosy which is served through in silico studies is the elimination of the collection, isolation, and purification steps of natural source material which possesses no activity. To be most effective in this strategy, large collections of data must be accumulated and interwoven for deep analysis. A group at Peking University has constructed the Universal Natural Products Database (UNPD) comprised of 197,201 natural products [66] as an important strategic effort, and used it to compare with a database of 1380 approved drugs. Through comparison with Lipinski's "rule of five" [67] it was found that 77.17% of the approved drugs obeyed the rule of five, while 52.0% of all natural products did, and 71.8% met at least three of the criteria. Obviously, this is not an appropriate comparison, since behind each approved drug are tens, may be hundreds, of thousands of molecules which may or may not have a relationship to the rule of five, and these rules were based originally on a dataset of known drug molecules. What it does illustrate is an amazing fit for over half of ALL natural products. It was indicated many years ago that 74% of all known, plant-derived alkaloids had never been tested in a single biological assay [68] , and thus the biological potential of alkaloids is simply vast.
Chemical space and chirality were also assessed [66] , from which it was deduced that the known drugs had fewer chiral centers and more aromatic and heterocyclic nuclei [69] . Using two, biologybased databases [70, 71] , a drug-target network database was established and used to examine the number of potential experimental targets. The average number of targets was 2.66, perhaps indicating a high degree of selectivity for a natural product once the target is identified.
However, one alkaloid, the indolocarbazole alkaloid staurosporine (whose biosynthesis we investigated 29 years ago [72, 73] !) displayed a staggering 298 targets, and the very common flavonoid quercetin revealed 82 targets [66] .
Turning to network pharmacology [74, 75] and conducting docking experiments with 332 target proteins, the UNPD set demonstrated over 65 million docked conformations, with targeted proteins providing an average of 25 hits, even when the docking score was set at higher than 9 for the original ligand molecule. Overall, the interpretation of these results led to twenty lead compounds with high prediction coefficients for further investigation for various forms of cancer, bacterial infections, asthma, and diabetes [66] .
The second, simpler, example concerns an "old" aporphine alkaloid, nuciferine, from lotus leaves, Nelumbo nucifera Gaertn. (Nelumbonaceae). Target profile clustering, after the nuciferine target profile was established, with searches for the regulation of lipase activity and for cell proliferation revealed possible anticancer activity. Experimental verification was achieved in vitro and in vivo, and the mechanism was established as occurring through inhibition of the P13K-AKT signaling pathway and of IL-1 levels in the cell lines [76] . The multiple, diverse use of established metabolites whose sustainable sourcing is established represents a further practical application of ecopharmacognosy [77] .
Conclusions
Natural medicinal agents are an everyday consideration in the health of the majority of the world; simply put, they matter. Their continued availability and accessibility are under threat from losses of biodiversity and traditional knowledge, climate change, and the overarching factors of a burgeoning and ageing population. This presentation of selected natural product areas offers sixty challenges to the natural products community in its various forms to address some pertinent issues in the development of natural products for Cordell enhanced global health by the year 2030. It also presents a brief discussion of the impacts of genomics, increased life expectancy, and artificial intelligence on ecopharmacognosy now and in the future.
